Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Int J Hematol ; 116(5): 647-658, 2022 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-35790696

RESUMO

A multicenter, randomized, open-label, phase III study was conducted to compare the efficacy and safety of intravenous ferric derisomaltose (FDI) versus saccharated ferric oxide (SFO) in Japanese patients with iron deficiency anemia associated with menorrhagia. FDI can be administered as a single dose up to 1000 mg, whereas SFO has a maximum single dose of 120 mg. The primary endpoint, which was the maximum change in hemoglobin concentration from baseline, was noninferior for the FDI group compared with the SFO group. The incidence of treatment-emergent adverse events was lower in the FDI group (66.2%) than in the SFO group (90.8%). Notably, the incidence of serum phosphorus level < 2.0 mg/dL was significantly lower in the FDI group (8.4%) than in the SFO group (83.2%), and severe hypophosphatemia (≤ 1.0 mg/dL) occurred in 6.7% of SFO­treated patients compared with none in the FDI group. The percentage of patients who achieved the cumulative total iron dose during the 8-week treatment period was higher in the FDI group (92.8%) than in the SFO group (43.2%). The study met its primary endpoint, and also demonstrated the tolerability of a high dose of FDI per infusion, with a lower incidence of hypophosphatemia.


Assuntos
Anemia Ferropriva , Compostos Férricos , Hipofosfatemia , Deficiências de Ferro , Menorragia , Feminino , Humanos , Anemia Ferropriva/tratamento farmacológico , Anemia Ferropriva/etiologia , Compostos Férricos/uso terapêutico , Óxido de Ferro Sacarado/efeitos adversos , Hemoglobinas/análise , Hipofosfatemia/induzido quimicamente , Ferro , Menorragia/complicações , Menorragia/tratamento farmacológico , Fósforo/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...